Danazol

$108.58$373.80

Danazol is a prescription drug manufactured by Barr Pharmaceutical Laboratory that is used to treat, among other conditions, fertility issues in both men and women. Danazol is a registered trademark of Barr Laboratories.

Clear
SKU: N/A Category:
Loading...

[vc_row][vc_column][vc_tta_tabs color=”black” spacing=”10″ gap=”10″ alignment=”center” active_section=”1″ css_animation=”rollIn”][vc_tta_section title=”Description” tab_id=”1500389328687-b3b21899-eef0″][vc_column_text]Danazol affects the ovaries and pituitary gland and prevents the release of certain hormones in the body. Danazol is used to treat endometriosis and fibrocystic breast disease. Danazol is also used to prevent attacks of angioedema in people with an inherited form of this disorder (hereditary angioedema). Danazol may also be used for purposes not listed in this medication guide.[/vc_column_text][/vc_tta_section][vc_tta_section title=”Use” tab_id=”1500389328750-d09ab9ad-1d93″][vc_column_text]Danazol is indicated for the treatment of endometriosis amenable to hormonal management. Fibrocystic Breast Disease. Most cases of symptomatic fibrocystic breast disease may be treated by simple measures (e.g., padded brassieres and analgesics). In infrequent patients, symptoms of pain and tenderness may be severe enough to warrant treatment by suppression of ovarian function. Danazol is usually effective in decreasing nodularity, pain, and tenderness. It should be stressed to the patient that this treatment is not innocuous in that it involves considerable alterations of hormone levels and that recurrence of symptoms is very common after cessation of therapy.[/vc_column_text][/vc_tta_section][vc_tta_section title=”How to Take” tab_id=”1500389387696-bdbeacb1-9ee0″][vc_column_text]

In moderate to severe disease, or in patients infertile due to endometriosis, a starting dose of 800 mg given in two divided doses is recommended. Amenorrhea and rapid response to painful symptoms is best achieved at this dosage level. Gradual downward titration to a dose sufficient to maintain amenorrhea may be considered depending upon patient response. For mild cases, an initial daily dose of 200 mg to 400 mg given in two divided doses is recommended and may be adjusted depending on patient response. Therapy should begin during menstruation. Otherwise, appropriate tests should be performed to ensure that the patient is not pregnant while on therapy with Danazol. (See CONTRAINDICATIONS and WARNINGS.) It is essential that therapy continue uninterrupted for 3 to 6 months but may be extended to 9 months if necessary. After termination of therapy, if symptoms recur, treatment can be reinstituted.

[/vc_column_text][/vc_tta_section][vc_tta_section title=”Side Effects” tab_id=”1500389412853-d02a327a-b319″][vc_column_text]

The following events have been reported in association with the use of Danazol: Androgen like effects include weight gain, acne and seborrhea. Mild hirsutism, edema, hair loss, voice change, which may take the form of hoarseness, sore throat or of instability or deepening of pitch, may occur and may persist after cessation of therapy. Hypertrophy of the clitoris is rare. Other possible endocrine effects include menstrual disturbances in the form of spotting, alteration of the timing of the cycle and amenorrhea. Although cyclical bleeding and ovulation usually return within 60-90 days after discontinuation of therapy with Danazol, persistent amenorrhea has occasionally been reported. Flushing, sweating, vaginal dryness and irritation and reduction in breast size, may reflect lowering of estrogen. Nervousness and emotional lability have been reported. In the male a modest reduction in spermatogenesis may be evident during treatment. Abnormalities in semen volume, viscosity, sperm count, and motility may occur in patients receiving long-term therapy. Hepatic dysfunction, as evidenced by reversible elevated serum enzymes and/or jaundice, has been reported in patients receiving a daily dosage of Danazol of 400 mg or more. It is recommended that patients receiving Danazol be monitored for hepatic dysfunction by laboratory tests and clinical observation. Serious hepatic toxicity including cholestatic jaundice, peliosis hepatis, and hepatic adenoma have been reported.

[/vc_column_text][/vc_tta_section][vc_tta_section title=”Precautions” tab_id=”1500389436547-e45a2b4c-4cda”][vc_column_text]

Because Danazol may cause some degree of fluid retention, conditions that might be influenced by this factor, such as epilepsy, migraine, or cardiac or renal dysfunction, require careful observation. Since hepatic dysfunction manifested by modest increases in serum transaminase levels has been reported in patients treated with Danazol, periodic liver function tests should be performed. Administration of Danazol has been reported to cause exacerbation of the manifestations of acute intermittent porphyria. Carcinogenesis, Mutagenesis, Impairment of Fertility No valid studies have been performed to assess the carcinogenicity of Danazol.

[/vc_column_text][/vc_tta_section][vc_tta_section title=”Drug Interactions” tab_id=”1500389457813-0dc3e294-95e1″][vc_column_text]

Prolongation of prothrombin time occurs in patients stabilized on warfarin. Therapy with Danazol may cause an increase in carbamazepine levels in patients taking both drugs. Laboratory Tests: Danazol treatment may interfere with laboratory determinations of testosterone, androstenedione and dehydroepiandrosterone.

[/vc_column_text][/vc_tta_section][/vc_tta_tabs][/vc_column][/vc_row]

Additional information

MG

200, 100, 50

PILLS

30, 60, 90, 120, 180

Reviews

There are no reviews yet.

Be the first to review “Danazol”

Your email address will not be published. Required fields are marked *